Tao (Tony) Li, PhD

Senior Director, Head of mRNA & Nanoparticle Platform
WuXi Biologics

Panelist

Tao (Tony) Li, PhD

Tao Li, PhD, is a results-driven senior director at WuXi Biologics who leads the design, scale-up, and commercialization of integrated mRNA and nanoparticle (NP) platforms—delivering end-to-end solutions from DNA synthesis to IND-enabling studies. He directs innovations in synthetic DNA, mRNA and targeted LNP technologies and partners across CMC, analytical/QC, and regulatory functions to accelerate clinical translation and ensure manufacturing and testing readiness.

Previously he set corporate R&D strategy at BCF, aligning product specifications with U.S., EU, and Asian regulations. At the U.S. FDA he specialized in analytical testing, lab automation, quality systems, audits, and training, standardizing workflows that strengthened compliance. Earlier roles include building LC–MS/MS testing programs, achieving >$150K in annual operational savings, expanding Asian market share by 50%, and conducting research on peptide conjugated PEGylated liposomes and bioinformatics. He holds a PhD from University of California, Davis in chemical engineering with designated emphasis in biotechnology.

Broadcast Date: 
  • Time: 

In vivo protein generation using nanoparticle delivery has evolved from vaccine applications into protein replacement, immunotherapy, and gene editing. Lipid nanoparticles (LNPs) and other nanocarriers remain the platform of choice for protecting cargo, enhancing cellular uptake, and facilitating endosomal escape. Scaling across oncology, infectious diseases, and genetic disorders demands progress on mRNA/DNA design, nanoparticle delivery, manufacturability, CMC strategy, cost, timeline, and speed. In this GEN webinar, our expert speaker, Tao (Tony) Li, PhD, will discuss nanoparticle delivery opportunities beyond oncology and infectious disease, compare emerging nanocarrier platforms, and examine important CMC considerations critical for progressing from research through IND. He will also present a case study on decorated mRNA/LNP for in vivo CAR T, from R&D gap evaluation and process development to full GMP manufacturing. Key takeaways from the webinar include:

  • A deeper understanding of the landscape beyond vaccine and oncology applications

  • How emerging platforms compare including their advantages, limitations, and development considerations

  • Key CMC challenges from research through IND including manufacturing, analytical characterization, and quality attributes

  • Strategic insights for future directions derived from fundamental questions

    • A live Q&A will follow the presentation offering you a chance to pose questions to our expert panelist.

    Produced with support from:

    The post <i>In Vivo</i> Protein Generation Using Nanoparticle Delivery: Emerging Platforms and CMC Strategies appeared first on GEN - Genetic Engineering and Biotechnology News.